Ron Philip was President and CEO of Orbital Therapeutics until its acquisition by Bristol Myers Squibb in 2025. Mr. Philip has over 30 years of experience in building companies, leading organizational growth, and guiding teams through the development of novel therapies.

Prior to joining Orbital, Mr. Philip served as the CEO of Spark Therapeutics, where he led the company through the commercial launch of the first approved gene therapy for a genetic disease. He led Spark’s transition and growth from founder-led to a fully integrated standalone business as part of the Roche Group. Before joining Spark, Mr. Philip spent a decade at Pfizer and Wyeth, where he held several senior leadership roles, including Regional President for Africa/Middle East, Head of Global Business Unit Strategy, Head of Business Development Search and Evaluation, and Commercial Development Lead within Pfizer’s innovative products business. Earlier in his career, he worked at Deloitte Consulting in the strategy and operations practice and at Merck & Co. in the company’s manufacturing and marketing divisions.

Mr. Philip currently serves as Executive Chair of CREATE Medicines and on the boards of directors of Harmony Biosciences and Avalo Therapeutics, as well as the Academy of Natural Sciences of Drexel University in Philadelphia, the Chamber of Commerce for Greater Philadelphia, and Life Sciences Pennsylvania. He received a B.S. in Computer Information Systems from Drexel University.